Contrasting Biodesix (NASDAQ:BDSX) & MDxHealth (NASDAQ:MDXH)

Biodesix (NASDAQ:BDSX) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Biodesix and MDxHealth”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$65.56 million	3.24	-$52.15 million	($0.39)	-3.74
MDxHealth	$84.71 million	0.04	-$43.10 million	($1.52)	-1.40

MDxHealth has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.0% of Biodesix shares are owned by institutional investors. 69.2% of Biodesix shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Biodesix and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	0	0	5	0	3.00
MDxHealth	0	0	4	0	3.00

Biodesix currently has a consensus price target of $3.06, indicating a potential upside of 109.59%. MDxHealth has a consensus price target of $7.00, indicating a potential upside of 228.64%. Given MDxHealth’s higher possible upside, analysts plainly believe MDxHealth is more favorable than Biodesix.

Profitability

This table compares Biodesix and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodesix	-66.84%	-275.79%	-43.05%
MDxHealth	-49.52%	-1,077.84%	-28.82%

Risk and Volatility

Biodesix has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Summary

MDxHealth beats Biodesix on 7 of the 13 factors compared between the two stocks.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.